Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1510415
European Journal of Endocrinology, Vol 151, Issue 4, 415-424
Copyright © 2004 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schleich, F
Right arrow Articles by Legros, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schleich, F
Right arrow Articles by Legros, J.
Articles

Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male

F Schleich and JJ Legros

Endocrinology Service, Interdisciplinary Aging Male Clinic, Faculty of Medicine, University of Liege, CHU Sart Tilman, 4000 Liege 1, Belgium.

The decrease in serum bioavailable testosterone may be responsible for the catabolic sequelae noticed in the aging man (decrease in libido, decrease in muscle mass, osteoporosis and increase in adiposity). After a brief review of androgen and lipid metabolism as well as their modifications with aging, we discuss current knowledge of the effects of androgen substitution on the lipid profile in hypogonadal men. The results of studies concerning the effect of androgen substitution therapy on lipids are conflicting but might be favorable. The small decrease in high-density lipoprotein cholesterol observed when administering standard dosages of testosterone is accompanied by a significant decrease in total cholesterol (CT) and low-density lipoprotein cholesterol. A counterbalancing of these effects plausibly accounts for the absence of increase cardiovascular risk. The currently available preparations are oral, injectable or transdermal formulations of natural testosterone. The development of new androgen preparations that are more potent, metabolically stable and tissue-specific will improve therapeutic benefits and reduce side effects.


This article has been cited by other articles:


Home page
 PhysiologyHome page
C. Baylis
Sexual Dimorphism of the Aging Kidney: Role of Nitric Oxide Deficiency
Physiology, June 1, 2008; 23(3): 142 - 150.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. A. Allan, B. J. G. Strauss, H. G. Burger, E. A. Forbes, and R. I. McLachlan
Testosterone Therapy Prevents Gain in Visceral Adipose Tissue and Loss of Skeletal Muscle in Nonobese Aging Men
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 139 - 146.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J Kratzsch, I Knerr, A Galler, T Kapellen, K Raile, A Korner, J Thiery, J Dotsch, and W Kiess
Metabolic decompensation in children with type 1 diabetes mellitus associated with increased serum levels of the soluble leptin receptor.
Eur. J. Endocrinol., October 1, 2006; 155(4): 609 - 614.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
A. Dokras, M. Bochner, E. Hollinrake, S. Markham, B. VanVoorhis, and D. H. Jagasia
Screening Women With Polycystic Ovary Syndrome for Metabolic Syndrome
Obstet. Gynecol., July 1, 2005; 106(1): 131 - 137.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 European Society of Endocrinology.